Blog

Healios Aims to Ready Stem-Cell Therapy for Eyesight By 2020 – Bloomberg


Bloomberg

Healios Aims to Ready StemCell Therapy for Eyesight By 2020
Bloomberg
The Japanese company's cell-based product is intended to treat macular degeneration, the leading cause of vision loss in the elderly. If successful, it would compete with Novartis AG's Lucentis, which generated $2.4 billion in sales last year. Pfizer

and more »

2015-06-19 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.